Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAFE: Teriflunomide in Relapsing Multiple Sclerosis
NCT03856619Phase 4Completed
- Sponsor
- Sanofi
- Start
- Mar 2019
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of teriflunomide in multiple sclerosis (MS), sponsored by Sanofi. Started Mar 2019; status: completed.
02
Drugs
teriflunomide
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT03856619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03856619.